Informal guidance and the FDA

Area of Science:

• Administrative Law
• Regulatory Policy
• Public Health Law

Background:

• The Food and Drug Administration (FDA) has increasingly utilized informal guidance documents over formal rulemaking.
• This shift impacts how the agency fulfills its statutory mandate and interacts with regulated entities.

Observation:

• The article traces the historical evolution of FDA's reliance on informal guidance over the past century.
• Key administrative law developments and regulatory regime modifications are examined as milestones.

Findings:

• The FDA's use of informal guidance has evolved significantly, raising questions about its binding nature and judicial deference.
• The analysis concludes that this trend has generally benefited regulated entities, the public, and the FDA.
• Doctrinal ambiguities regarding FDA advisory opinions and judicial review are addressed.

Implications:

• The findings suggest that informal guidance, while raising legal questions, offers benefits to FDA stakeholders.
• The article proposes modest reforms to optimize the use of informal guidance.
• Understanding these dynamics is crucial for navigating FDA regulations and policy.